Skip to content

A biomarker-targeted clinical trial to optimize treatment for patients with chronic kidney disease

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-507449-27-01
Enrollment
115
Registered
2025-04-08
Start date
2025-06-20
Completion date
Unknown
Last updated
2026-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease

Brief summary

Chronic eGFR slope, defined as mean annual rate of change in eGFR from week 26 to week 104.

Detailed description

Change in eGFR from baseline to week 112 (end of study)., Change in eGFR from baseline to week 104 (end of treatment)., Change in albuminuria from baseline to week 104., Change in KidneyIntelX score from baseline to week 104., FOR ITALY ONLY: Change in UEGF from baseline to week 26 and association between change in uEGF and change in albuminuria (Exploratory endpoint)

Interventions

DRUGFinerenone
DRUGDAPAGLIFLOZIN
DRUGSEMAGLUTIDE

Sponsors

Steno Diabetes Center Copenhagen
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Chronic eGFR slope, defined as mean annual rate of change in eGFR from week 26 to week 104.

Secondary

MeasureTime frame
Change in eGFR from baseline to week 112 (end of study)., Change in eGFR from baseline to week 104 (end of treatment)., Change in albuminuria from baseline to week 104., Change in KidneyIntelX score from baseline to week 104., FOR ITALY ONLY: Change in UEGF from baseline to week 26 and association between change in uEGF and change in albuminuria (Exploratory endpoint)

Countries

Denmark, Germany, Italy, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026